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 Abstract 
Dengue fever occurs by Infection of mosquito-borne dengue virus and sometimes fatal dengue hemorrhagic fever. 
Every year cases of dengue infections are increasing. This suggests that the virus is becoming more virulent and its 
transmission is expanding. Nevertheless, no effective treatment for dengue infection currently exists. This paper has 
focused several potential targets for antiviral drug development against flavivirus. We discuss the flavivirus genome, NS1, 
NS2, NS3, Envelope protein and NS5 MTase domain and NS5 RdRp domain as a potential drug targets. 
Keywords: Flavivirus, Dengue fever, Aedesaegypti, Structural protein, RNA dependent RNA polymerase. 
1. Introduction  
Flaviviridaeae are coated viruses that possess 
positive strand RNA genome that have been systamatized 
into three genera, Hepacivirus, Pestivirus, and Flavivirus. 
[1,2]. Members of the Flavivirus genus, e.g., dengue virus 
(DENV), yellow fever virus(YFV), Japanese encephalitis 
virus (JEV), tick-borne encephalitis virus, and West Nile 
virus (WNV), has significant role in medical science as an 
important arthropod-borne pathogens afflicting humans. 
Dengue fever is considered as an ancient disease. 
It was first recorded in Chinese encyclopedia of disease and 
symptoms published during the Chin Dynasty (265 to 420 
AD) [3]. In ancient Chinese medical literatures it referred as 
the Water poison because its vector is a flying insect which 
breed in clean water. Modern science has now approved 
that dengue fever is a viral disease transmitted between 
human hosts by Aedesaegypti. Aedesaegypti plays a 
significant role in the outbreak of dengue fever because of 
its well adaptation in urban living environment [4].  
Dengue virus (DENV) is one of the most 
important arboviral infections. It affects more than 100 
countries in the tropical and sub-tropical regions of the 
world [5]. Gubler et al found that every year dengue affects  
 
 
50 million people which lead to more than 25,000 deaths 
because two fifth of the world population lives in areas 
where there is a risk of dengue infection [6]. Sickness 
caused by dengue virus comprises undifferentiated fever, 
dengue fever (DF), dengue hemorrhagic fever (DHF), and 
dengue shock syndrome (DSS) [7, 8]. 
As reported by WHO’s 1997 documentation DF is 
clinically characterized as an intense feverish disease with 
two or more symptoms of retroorbital irritation, myalgia, 
headache, arthralgia, rash, and so on. Manifestations of DF 
can retain 2–7 days. DHF is described by the following 
norms: persistent high fever, hemorrhage tendency, 
hemoconcentration (>20%), and platelet counts (<100,000) 
[9- 12]. This paper starts with flavivirus genome, 
replication and their targets. This paper is a review of drug 
target of dengue which encourages drug development 
efforts. 
Positive strand RNA genome of dengue virus 
encodes three structural proteins (C-prM-E), and seven 
nonstructural (NS) proteins (NS1-NS2A-NS2B-NS3-
NS4A-NS4B-NS5), as schematically shown in Figure 1. 
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Figure 1: Above figure show organization of flavivirus 
genome and polyprotein processing 
 
DENV genome contain 11 kb positive-sense, 
single-stranded RNA genome consist of a single open 
reading frame for 3 structural proteins (capsid (C), 
precursor membrane (prM) and envelope (E)) and 7 non-
structural proteins (NS1-NS2A, NS2B, NS3, NS4A, NS4B, 
NS5). The open reading frame is bordered by untranslated 
regions. Sites of polyprotein cleavage mediated by the viral 
NS2B, NS3 and by host signalase and furin are shown, and 
the enzymatic activities of NS3 and NS5 are also indicated 
[13]. 
Entry of DENV in the host cell is occurred by 
receptor mediated endocytosis. Upon internalization and 
acidification of the endosome, fusion of viral and vesicular 
membranes allows release of the genomic RNA into the 
cytoplasm, which serves as mRNA. Translation of the 
single ORF at the rough ER produces a large polyprotein 
that is cleaved co- and posttranslationally into the mature 
proteins [14]. 
 
Figure 2: A typical life cycle after entering the host 
genome appears [14] 
1.1 Drug targets for dengue 
Dengue is a life threatening disease, No vaccine 
has been developed till now [15]. The main reason of this is 
presence of its four serotypes. It is compulsory to find a 
right drug target for dengue treatment so that an effective 
drug can be designed. Till now so much work has been 
done on many proteins of DENV. This review shall now 
concentrate all finding other potential targets for treatment. 
NS2-NS3 
NS3 is considered one of the most important 
nonstructural proteins because it has serine protease activity 
at its N terminal which cleaves the viral poly protein at its 
various regions. This function of NS3 is depends on its 
interaction with another nonstructural protein i.e. NS2B. 
Besides this NS2 also interact with other protein of DENV 
and these interactions play vital role in DENV life cycle so 
both NS2 & NS3 can be potential drug target. The table 
below now list the important landmark papers concerned 
with findings related to the protein. 
Table 1: Authors finding on NS2-NS3 
S. No. Authors Findings Remarks 
1. Padmanaban 
Senthilvel et al 
[16] 
They find the Flavonoid quercetin, found   in   papaya, with 
highest binding energy against NS2B-NS3 protease. 
 
2. Rothan et al.[17] They tested antiviral Activities in medicinal plants extracts 
against dengue virus using dengue NS2B-NS3 Protease assay. 
 
3. Rothan et al.[18] They worked on retrocyclin-1(RC-1) and reported that RC-1 
reduces the rate of DENV replication and we may get 
recombinant RC-1 in E.coli. They considered recombinant RC-1 
as a potent inhibitor. 
 
4. Ayub et al.[19] They analysed the conserved domains of NS3. They suggested 
that these domains of the NS3 sequence may be helpful in 
developing antiviral drugs. 
One of the drawbacks with this 
target is that helicase activity of 
NS3 is not well understood. 
5. Muslum et al. 
[20] 
They identified new allosteric site of NS2B-NS3 Protease. They 
utilized a define panel of just eight cysteine variants and only 
five cysteine reactive probes. They considered this site useful in 
the development of drug which allosterically inhibits NS2B-NS3 
protease. 
 
6. Leopoldo et al. 
[21] 
They observed the importance of NS3 enhanced RNA- RNA 
interactions between molecules which is necessary for viral 
RNA synthesis. They proposed that, NS3 can regulate the 
folding or unfolding of viral RNA structures according to the 
ATP availability. 
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NS5 
DENV genome comprises about 11000 
nucleotides in which NS5 is considered as a largest and 
most conserved NS protein. Its N terminal contains 
methyltransferase domain and C terminal contains RNA 
dependent RNA polymerase. Both domains have showed 
important role in viral replication. NS5 is also well 
characterized structurally and functionally. In future this 
target will show great contribution in the path of dengue 
drug development. 
  
Table 2: Authors finding on NS5 
S. No. Authors Findings Remarks 
1. Hongping Dong et 
al [22] 
They reported the methyltransferase activity of dengue virus (DENV) which 
sequentially methylates the guanine N-7 and ribose2′-O positions of viral RNA cap 
(GpppA→m7GpppA→m7GpppAm). 
 
2. Lihui et al [23] They demonstrated necessities of the N7 methylation activity for the WNV life   cycle   
and,   represented   the methyltransferase as a novel and promising target for flavivirus 
treatment. 
 
3. Christian et al [24] They crystallized the RNA-dependent RNA polymerase (RdRp) domain of dengue 
virus serotype 3 (DENV-3) through a highly reproducible method.  This method 
allowed structure refinement to a 1.79-Å resolution   and revealed amino acids not seen 
previously. DENV-3 polymerase/inhibitor cocrystal structure at a 2.1-Å resolution was 
also conferred by them. 
 
4. Egloff et al [25] They   worked   on   active   MTase domain from DENV and represented their crystal 
structure. This structural information gives a unique ground for drug design against this 
emerging flavivirus. 
 
 
Envelope Protein 
Envelope protein is made up of three domains involved in virus entry into host cell. It is well studied protein so it 
will be good option to find out inhibitor against Envelope protein. 
 
Table 3: Authors finding on Envelope Protein 
S. No. Authors Findings Remarks 
1. Wahala et al [26] They proposed that human antibodies directed to other epitopes on the virus are 
primarily responsible for DENV neutralization. Their results have implications for 
understanding protective immunity following natural DENV infection and for 
evaluating DENV vaccines.  
 
2. Chiang et al [27] They proposed the lapidated subunit vaccine for DEN serotypes and also other 
flavivirus members. 
 
 
Capsid Protein 
It is structural proteins of DENV which interact with viral RNA and form nucleocapsid. By identifying inhibitors 
of this interaction we can devolve potential drugs. 
 
Table 4: Authors finding on Capsid Protein 
S. No. Authors Findings Remarks 
1. Marcelo et al [28] They found a link between lipid droplet metabolism and viral replication and suggested 
that change in this mechanism of lipid droplets could control viral replication. 
 
 
NS1 Protein 
NS1 is non-structural glycoprotein. It is found on the cell surface and released into extracellular space. The 
flavivirus NS1 protein bears certain interesting and peculiar properties as compared to nonstructural proteins encoded by 
other RNA viruses this will make ideal target for drug development but structural biological information is very limited. 
This has hampered a complete understanding of its functions. 
 
Table 5: Authors finding on NS1 Protein 
S. No. Authors Findings Remarks 
1. Yung-Chun Chuang, Shu-Ying Wang, Yee-Shin 
Lin, Hong- Ru Chen and Trai- Ming Yeh [29]. 
They did most of their work On NS1 and the antibodies 
and represented their role during Infection. 
 
2. Muhammad Tahirul Qamar, Arooj Mumtaz, Rabbia 
Naseem, Amna   Ali, Tabeer Fatima, Tehreem 
Jabbar, Zubair Ahmad & Usman Ali Ashfaq [30]. 
They focused on NS1 protein and concluded that 
flavonoids could serve as antiviral drugs for dengue 
infections. 
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2.  Conclusion 
The purpose of this review is to point out several 
possible targets of dengue for antiviral drugs development. 
But, we feel NS5 may prove to be the target with the best 
chance of success.NS5 is the largest DENV protein, sharing 
a minimum of 67% amino acid sequence identity across the 
four DENV serotypes, NS5 is also the most conserved viral 
protein. 
As per the target is concerned, NS5 can play the 
most appropriate role for the same. Being on the top of the 
list according to its size in different DENV serotypes it has 
sequence identity in 67% part of amino acids in all four 
DENV serotypes. RdRp domain of NS5 protein forms part 
of a multimeric complex that plays a crucial role in viral 
genome replication, 
The development of new anti-dengue products 
from bioactive compounds is necessary in order to find 
more effective and less toxic anti-dengue drugs. 
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